Brief: Sangamo Therapeutics And Voyager Therapeutics Enter License Agreement

Sangamo Therapeutics

29/06/2023 13:25

June 29 (Reuters) - Sangamo Therapeutics Inc  SGMO.O :
    * SANGAMO THERAPEUTICS AND VOYAGER THERAPEUTICS ENTER
LICENSE
AGREEMENT FOR EPIGENETIC REGULATION TREATMENT OF PRION DISEASE
    * SANGAMO HAS RECEIVED A NON-EXCLUSIVE LICENSE TO COMBINE A
VOYAGER TRACER CAPSID WITH SANGAMO'S ZF-TRS
    * EXPECTS TO SUBMIT A POTENTIAL IND FOR A PRODUCT CANDIDATE
TREATING PRION DISEASE IN 2025
    * SANGAMO THERAPEUTICS- VOYAGER ELIGIBLE TO EARN CERTAIN
LICENSE
FEES, ROYALTIES ON POTENTIAL COMMERCIAL SALES OF ANY PRODUCTS
USING VOYAGER'S CAPSID

Source text for Eikon:  ID:nBw2cslC7a 
Further company coverage:  SGMO.O 

 ((Reuters.Briefs@thomsonreuters.com;))